Review of BCL2 inhibitors for the treatment of Waldenström’s macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma
Lymphoplasmacytic lymphoma (LPL) is a relatively rare form of indolent B-cell non-Hodgkin’s lymphoma, termed Waldenström’s macroglobulinaemia (WM) in the presence of an IgM paraprotein. Although traditionally treated with combination chemoimmunotherapy, the management is evolving in the era of targe...
שמור ב:
| Principais autores: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2024-11-01
|
| סדרה: | Frontiers in Oncology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1490202/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|